OR WAIT null SECS
Roche launched imCORE, a global network of cancer immunotherapy centers of excellence.
On Nov. 15, 2016, Roche launched immunotherapy Centers of Research Excellence (imCORE), a global network of cancer researchers focused on developing new treatments. This network brings together scientific and clinical experts in cancer immunotherapy to collaborate in investigating new treatment approaches. The goal is to rapidly initiate pre-clinical and clinical research based on the latest scientific discoveries and to aggregate and share data to accelerate the search for cures. The imCORE Network will focus on identifying approaches to expand the number of people who benefit from cancer immunotherapy by exploring new ways to activate a person’s immune system to fight their cancer.
imCORE is a global network of basic and clinical scientists from 21 leading academic research institutions in cancer immunotherapy. These scientists will collaborate with scientists from Roche and Genentech with the goal of developing potential cancer cures. Roche is working in collaboration with the network on existing and new investigational medicines, diagnostic technologies, and emerging data. The network will also closely collaborate to identify and prioritize new treatment approaches and to conduct clinical trials to accelerate progress in the field. Roche will invest up to 100 million Swiss Francs to support basic and clinical research collaborations related to cancer immunotherapy. This investment is incremental to Roche’s on-going research and development of investigational medicines and treatment approaches in the field of cancer immunotherapy.